Virginia Commonwealth University

Allos Therapeutics, Inc.

Other

Stephen J Hoffman

Donald J Abraham

Gajanan S Joshi

Richmond E Danso-Danquah

Martin K Safo

Melissa Grella

Sanjeev Kulkarni

Amal Yousseff

Michael J Gerber

James C Burnett

Telih Boyiri

Changging Wang

Changquing Wang

A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.

Substituted chiral allosteric hemoglobin modifiers

Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).

Allosteric inhibitors of pyruvate kinase

Chemical structures have been identified which allosterically modify pyrvate kinase and either inhibit or activate enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate.

Allosteric hemoglobin modifier compounds are disclosed that clear carbon monoxide hemoglobin from a host animal.

Treatment for carbon monoxide poisoning

Growing community of inventors

Carlisle, MA, United States of America

Stephen J Hoffman